scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1007018875 |
P356 | DOI | 10.1186/S12936-015-0972-0 |
P932 | PMC publication ID | 4640242 |
P698 | PubMed publication ID | 26552428 |
P5875 | ResearchGate publication ID | 283740945 |
P50 | author | Marga van de Vegte-Bolmer | Q45380602 |
Michael Theisen | Q58310143 | ||
Robert Sauerwein | Q72530989 | ||
Will Roeffen | Q72536015 | ||
P2093 | author name string | Michael Christiansen | |
Shrawan Kumar Singh | |||
Theo Arens | |||
Swarnendu Kaviraj | |||
Gorm Andersen | |||
GeertJan van Gemert | |||
Laxman Sevargave | |||
P2860 | cites work | A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum | Q24814432 |
The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania | Q28744581 | ||
A central role for P48/45 in malaria parasite male gamete fertility | Q30043154 | ||
A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies | Q33198902 | ||
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. | Q33350210 | ||
A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli | Q33485233 | ||
A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children | Q33987686 | ||
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. | Q35809113 | ||
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito | Q36351262 | ||
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections | Q36547334 | ||
Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice | Q36670217 | ||
Surface antigens of Plasmodium falciparum gametocytes--a new class of transmission-blocking vaccine targets? | Q37487002 | ||
Adjuvants for malaria vaccines | Q37582428 | ||
Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura | Q38995073 | ||
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate | Q38995083 | ||
A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies | Q39467691 | ||
A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages | Q39520295 | ||
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion | Q39812986 | ||
Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera | Q40959724 | ||
Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells | Q41003251 | ||
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon | Q41877888 | ||
Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes | Q41946006 | ||
Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon | Q44137386 | ||
Plasmodium falciparum: membrane feeding assays and competition ELISAs for the measurement of transmission reduction in sera from Cameroon | Q44140956 | ||
Transmission blocking malaria vaccines | Q44145217 | ||
Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes | Q44146493 | ||
Changes in Anopheles funestus biting behavior following universal coverage of long-lasting insecticidal nets in Benin | Q44165680 | ||
Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. | Q47829675 | ||
Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. | Q47837358 | ||
Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast | Q47857505 | ||
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate | Q47973517 | ||
Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial | Q48034345 | ||
Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum | Q48103837 | ||
Plasmodium falciparum: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen | Q73509627 | ||
P921 | main subject | Plasmodium falciparum | Q311383 |
P304 | page(s) | 443 | |
P577 | publication date | 2015-11-09 | |
P1433 | published in | Malaria Journal | Q15749954 |
P1476 | title | Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants | |
P478 | volume | 14 |
Q91723010 | A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria |
Q37736878 | A review on Lactococcus lactis: from food to factory |
Q36906995 | Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail |
Q40110842 | Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana |
Q40212118 | Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses |
Q96813794 | Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230 |
Q33750638 | Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine |
Q40159945 | Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite |
Q28365035 | Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate |
Q92001627 | Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites |
Q47137421 | In Silico Validation of D7 Salivary Protein-derived B- and T-cell Epitopes of Aedes aegypti as Potential Vaccine to Prevent Transmission of Flaviviruses and Togaviruses to Humans |
Q47251697 | Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity |
Q90101806 | Statistical Methods for Standard Membrane-Feeding Assays to Measure Transmission Blocking or Reducing Activity in Malaria |
Q38775588 | Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine |
Search more.